Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
A Pilot Feasibility Study of Durvalumab (MEDI4736) and Tremelimumab Following Radioembolization in Patients With Metastatic Microsatellite Stable (MSS) Colorectal Cancer to the Liver
Sponsor: City of Hope Medical Center
A PHASE1 clinical study on MLH1 Gene Mutation and MSH6 Gene Mutation, this trial is completed. The trial is conducted by City of Hope Medical Center and has accumulated 10 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Oct 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting · Phase: NA → PHASE1
-
Feb 2017 — Oct 2017 [monthly]
Not Yet Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- City of Hope Medical Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .